These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

477 related articles for article (PubMed ID: 33934451)

  • 1. Casp8 acts through A20 to inhibit PD-L1 expression: The mechanism and its implication in immunotherapy.
    Zou J; Xia H; Zhang C; Xu H; Tang Q; Zhu G; Li J; Bi F
    Cancer Sci; 2021 Jul; 112(7):2664-2678. PubMed ID: 33934451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overexpression of DAPK1-mediated inhibition of IKKβ/CSN5/PD-L1 axis enhances natural killer cell killing ability and inhibits tumor immune evasion in gastric cancer.
    Guo Z; Zhou C; Zhou L; Wang Z; Zhu X; Mu X
    Cell Immunol; 2022 Feb; 372():104469. PubMed ID: 35114597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells.
    Lee MY; Robbins Y; Sievers C; Friedman J; Abdul Sater H; Clavijo PE; Judd N; Tsong E; Silvin C; Soon-Shiong P; Padget MR; Schlom J; Hodge J; Hinrichs C; Allen C
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33741731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
    Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A20 regulates the therapeutic effect of anti-PD-1 immunotherapy in melanoma.
    Guo W; Ma J; Guo S; Wang H; Wang S; Shi Q; Liu L; Zhao T; Yang F; Chen S; Chen J; Zhao J; Yu C; Yi X; Yang Y; Ma J; Ni Q; Zhu G; Gao T; Li C
    J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33298620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metformin Suppresses Both PD-L1 Expression in Cancer Cells and Cancer-Induced PD-1 Expression in Immune Cells to Promote Antitumor Immunity.
    Park SH; Lee J; Yun HJ; Kim SH; Lee JH
    Ann Lab Med; 2024 Sep; 44(5):426-436. PubMed ID: 38529546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HLA class I downregulation is associated with enhanced NK-cell killing of melanoma cells with acquired drug resistance to BRAF inhibitors.
    Sottile R; Pangigadde PN; Tan T; Anichini A; Sabbatino F; Trecroci F; Favoino E; Orgiano L; Roberts J; Ferrone S; Kärre K; Colucci F; Carbone E
    Eur J Immunol; 2016 Feb; 46(2):409-19. PubMed ID: 26564811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Down-regulation of A20 promotes immune escape of lung adenocarcinomas.
    Breitenecker K; Homolya M; Luca AC; Lang V; Trenk C; Petroczi G; Mohrherr J; Horvath J; Moritsch S; Haas L; Kurnaeva M; Eferl R; Stoiber D; Moriggl R; Bilban M; Obenauf AC; Ferran C; Dome B; Laszlo V; Győrffy B; Dezso K; Moldvay J; Casanova E; Moll HP
    Sci Transl Med; 2021 Jul; 13(601):. PubMed ID: 34233950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IFN-gamma-induced PD-L1 expression in melanoma depends on p53 expression.
    Thiem A; Hesbacher S; Kneitz H; di Primio T; Heppt MV; Hermanns HM; Goebeler M; Meierjohann S; Houben R; Schrama D
    J Exp Clin Cancer Res; 2019 Sep; 38(1):397. PubMed ID: 31506076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SOX2 promotes resistance of melanoma with PD-L1 high expression to T-cell-mediated cytotoxicity that can be reversed by SAHA.
    Wu R; Wang C; Li Z; Xiao J; Li C; Wang X; Kong P; Cao J; Huang F; Li Z; Huang Y; Chen Y; Li X; Yang D; Zhang H; Mai J; Feng G; Deng R; Zhu X
    J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33158915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy.
    Hailemichael Y; Woods A; Fu T; He Q; Nielsen MC; Hasan F; Roszik J; Xiao Z; Vianden C; Khong H; Singh M; Sharma M; Faak F; Moore D; Dai Z; Anthony SM; Schluns KS; Sharma P; Engelhard VH; Overwijk WW
    J Clin Invest; 2018 Apr; 128(4):1338-1354. PubMed ID: 29480817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A secondary role for hypoxia and HIF1 in the regulation of (IFNγ-induced) PD-L1 expression in melanoma.
    van Duijn A; Willemsen KJ; van Uden NOP; Hoyng L; Erades S; Koster J; Luiten RM; Bakker WJ
    Cancer Immunol Immunother; 2022 Mar; 71(3):529-540. PubMed ID: 34268602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A TLR3-Specific Adjuvant Relieves Innate Resistance to PD-L1 Blockade without Cytokine Toxicity in Tumor Vaccine Immunotherapy.
    Takeda Y; Kataoka K; Yamagishi J; Ogawa S; Seya T; Matsumoto M
    Cell Rep; 2017 May; 19(9):1874-1887. PubMed ID: 28564605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increase in Efficacy of Checkpoint Inhibition by Cytokine-Induced-Killer Cells as a Combination Immunotherapy for Renal Cancer.
    Dehno MN; Li Y; Weiher H; Schmidt-Wolf IGH
    Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32349280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regorafenib Promotes Antitumor Immunity via Inhibiting PD-L1 and IDO1 Expression in Melanoma.
    Wu RY; Kong PF; Xia LP; Huang Y; Li ZL; Tang YY; Chen YH; Li X; Senthilkumar R; Zhang HL; Sun T; Xu XL; Yu Y; Mai J; Peng XD; Yang D; Zhou LH; Feng GK; Deng R; Zhu XF
    Clin Cancer Res; 2019 Jul; 25(14):4530-4541. PubMed ID: 30940655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells.
    Boyerinas B; Jochems C; Fantini M; Heery CR; Gulley JL; Tsang KY; Schlom J
    Cancer Immunol Res; 2015 Oct; 3(10):1148-1157. PubMed ID: 26014098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apigenin suppresses PD-L1 expression in melanoma and host dendritic cells to elicit synergistic therapeutic effects.
    Xu L; Zhang Y; Tian K; Chen X; Zhang R; Mu X; Wu Y; Wang D; Wang S; Liu F; Wang T; Zhang J; Liu S; Zhang Y; Tu C; Liu H
    J Exp Clin Cancer Res; 2018 Oct; 37(1):261. PubMed ID: 30373602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ADORA1 Inhibition Promotes Tumor Immune Evasion by Regulating the ATF3-PD-L1 Axis.
    Liu H; Kuang X; Zhang Y; Ye Y; Li J; Liang L; Xie Z; Weng L; Guo J; Li H; Ma F; Chen X; Zhao S; Su J; Yang N; Fang F; Xie Y; Tao J; Zhang J; Chen M; Peng C; Sun L; Zhang X; Liu J; Han L; Xu X; Hung MC; Chen X
    Cancer Cell; 2020 Mar; 37(3):324-339.e8. PubMed ID: 32183950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
    Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
    Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nafamostat mesilate, a serine protease inhibitor, suppresses interferon-gamma-induced up-regulation of programmed cell death ligand 1 in human cancer cells.
    Homma S; Hayashi K; Yoshida K; Sagawa Y; Kamata Y; Ito M
    Int Immunopharmacol; 2018 Jan; 54():39-45. PubMed ID: 29100036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.